MedPath

The Cleveland Clinic Foundation

The Cleveland Clinic Foundation logo
🇺🇸United States
Ownership
Subsidiary, Private
Established
1921-01-01
Employees
1K
Market Cap
-
Website
http://www.clevelandclinic.org

Clinical Trials

795

Active:44
Completed:452

Trial Phases

6 Phases

Early Phase 1:18
Phase 1:30
Phase 2:48
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (591 trials with phase data)• Click on a phase to view related trials

Not Applicable
404 (68.4%)
Phase 4
64 (10.8%)
Phase 2
48 (8.1%)
Phase 1
30 (5.1%)
Phase 3
27 (4.6%)
Early Phase 1
18 (3.0%)

Developing MRI Technologies for Atrial Fibrillation

Not yet recruiting
Conditions
Atrial Fibrillation (AF)
First Posted Date
2025-07-24
Last Posted Date
2025-07-24
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
50
Registration Number
NCT07083115

Longitudinal Validation of CIRC Technologies

Not yet recruiting
Conditions
Cardiovascular Diseases
Heart Failure
Ischemic Heart Disease
Non-ischemic Cardiomyopathy
Valvular Heart Disease
Metabolic Cardiomyopathy
Congenital Heart Disease
Aortic Diseases
Atrial Fibrillation
Ventricular Fibrillation
First Posted Date
2025-07-23
Last Posted Date
2025-07-23
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
1000
Registration Number
NCT07081711

Virtual Patient Groups for Sarcoidosis Associated Fatigue

Not Applicable
Not yet recruiting
Conditions
Sarcoidosis
Fatigue
Depression
Anxiety
Mental Health
First Posted Date
2025-07-20
Last Posted Date
2025-07-20
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
80
Registration Number
NCT07073963
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

Gluten Free Diet in Hashimoto's Hypothyroidism

Not Applicable
Recruiting
Conditions
Hypothyroidism
Hashimoto Disease
First Posted Date
2025-07-11
Last Posted Date
2025-07-11
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
50
Registration Number
NCT07060118
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD

Not Applicable
Not yet recruiting
Conditions
COPD
Emphysema
Sarcopenia
First Posted Date
2025-07-11
Last Posted Date
2025-07-20
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
80
Registration Number
NCT07059637
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 159
  • Next

News

Biomerica Appoints Scott Madel as Chief Commercial Officer to Drive inFoods IBS Test Commercialization

Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.

LifePlus Achieves Clinical Validation for Revolutionary Non-Invasive Glucose and Blood Pressure Monitoring Device

LifePlus announced clinical validation of LifeLeaf®, the world's first non-invasive wearable for continuous glucose and blood pressure tracking, tested at Mayo Clinic, Cleveland Clinic, and other global centers.

FDA Approves First Bone Growth Accelerator for Spinal Fusion Surgery

Cerapedics received FDA premarket approval for PearlMatrix P-15 Peptide Enhanced Bone Graft, the first proven bone growth accelerator for lumbar fusion procedures.

FDA Approves First Integrated Sacral Neuromodulation System for Urinary Urge Incontinence

The FDA has approved Neuspera Medical's integrated sacral neuromodulation (iSNM) system, the first battery-free device for treating urinary urge incontinence (UUI).

Biologic Therapies Transform Respiratory Care as Clinicians Embrace Earlier, Precision-Based Treatment Strategies

Biologic therapies including dupilumab, benralizumab, and tezepelumab have revolutionized asthma management by enabling biomarker-driven treatment strategies beyond traditional allergen or eosinophil-based models.

ANGLE's Parsortix System Enables Breakthrough Cancer Research Revealing CTC Clusters as Key Metastatic Drivers

ANGLE's Parsortix system has enabled multiple breakthrough studies published in high-impact journals, revealing novel insights into circulating tumor cell biology and cancer metastasis mechanisms.

Mixed Results for Adjuvant Immunotherapy in High-Risk Cutaneous Squamous Cell Carcinoma

The phase 3 KEYNOTE-630 trial found that adjuvant pembrolizumab did not significantly improve progression-free survival in patients with high-risk cutaneous squamous cell carcinoma following surgery and radiation.

Atezolizumab Plus Chemotherapy Reduces Recurrence Risk by 50% in Stage III dMMR Colon Cancer

The phase 3 ATOMIC trial demonstrated that adding atezolizumab to standard chemotherapy reduced the risk of recurrence or death by 50% in patients with stage III dMMR colon cancer.

Large Norwegian Study Finds No Increased Risk of Autism or ADHD in Children Exposed to Triptans During Pregnancy

A comprehensive Norwegian population study of 26,210 pregnancies found no increased risk of neurodevelopmental disorders, including autism and ADHD, in children whose mothers used triptans for migraine treatment during pregnancy.

Ellipsoid Zone Integrity Linked to Visual Function in Geographic Atrophy Patients

Post-hoc analysis of GATHER1 and GATHER2 trials reveals a clear structure-function relationship between ellipsoid zone integrity and visual acuity in geographic atrophy patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.